In cholesterol biosynthesis pathways, 3-hydroxy-3-methylglutaryl-CoA reductase (HMGCR) is the rate-limiting enzyme in in the conversion of HMG-CoA to mevalonate, whose expression is upregulated in gastric cancer, glioblastoma and prostate cancer. Here, HMGCR is linked to prostate carcinoma.